Investigational drug makes earlier hospital discharge possible following surgery

September 27, 2001

St. Louis, Sept. 27, 2001 - A team of researchers, led by anesthesiologists at Washington University School of Medicine in St. Louis, has found that an investigational drug helps patients recover bowel function more quickly after abdominal surgery, leading to less post-operative illness and quicker discharge from the hospital.

The researchers say the drug, ADL 8-2698, blocks the actions of morphine and other opioids in the intestines without inhibiting their ability to relieve pain. The finding is reported in this week's New England Journal of Medicine. "Return of bowel function is one of the key indicators of recovery following surgery," said principal investigator Andrea Kurz. M.D., an assistant professor and director of the Division of Clinical Research in the Department of Anesthesiology at Washington University School of Medicine, as well as associate director of the Outcomes Research ™ Institute, an international group of researchers. "One of the ways that we know a person is about ready to go home is that they pass gas, and that indicates their bowel function is returning to normal."

Drugs such as morphine and other opioids are very good at relieving post-operative pain, but they also act on opioid receptors in the gut, blocking normal GI function. Kurz found that ADL 8-2698 kept the opioids from affecting those receptors without blocking the beneficial pain-relieving actions of the drug in the brain.

The investigators studied 78 patients undergoing abdominal surgery -- either colectomy or hysterectomy -- and divided the patients into three groups of 26 each. One group received an inactive placebo. The second study group received a 1 mg dose of ADL 8-2698, and the third group got a 6 mg dose of the investigational drug. All three groups received identical-looking capsules two hours before surgery and again twice daily until they either had a full return of bowel function or were discharged from the hospital. Patients who received 6 mg of ADL 8-2698 reported no greater pain and did not receive more pain medication, but they did have much quicker recovery of bowel function. Those who received 1 mg of ADL 8-2698 had smaller, less significant improvements.

The median length of time before first flatus decreased from 70 hours in the placebo group to 49 hours in the group that got 6 mg doses of the drug. Time to first bowel movement declined from 111 hours to 70. And the time at which patients were deemed ready for discharge decreased from 91 hours in the placebo group to 68 hours in the 6 mg group.

"A big advantage of this drug is that it's poorly absorbed," Kurz said. "It acts selectively on the periphery -- the bowel in this case -- without crossing into the bloodstream and subsequently into the brain. There are many drugs that antagonize opioids, but most of them also cross into the brain, too. That limits the analgesic effects of the opioids, and patients end up having pain."

Patients who received the 6 mg dose of the drug also had significant decreases in nausea and vomiting in the hours and days after surgery. And because patients who were given the drug were ready to go home sooner, it follows that the drug has the potential to lower health care costs. "We did not evaluate cost effectiveness in this particular study, but showing that most patients are discharged about a day earlier would suggest that the cost savings are substantial," Kurz said. Kurz and colleagues continue to study the drug in abdominal surgery patients, hoping to fine-tune the dosage at which the drug will work most effectively. They also hope to study its actions in patients undergoing other types of surgery.
Akiko Taguchi, et. al., "Selective Postoperative Inhibition of Gastrointestinal Opioid Receptors," New England Journal of Medicine, vol. 345(13), 935-940, Sept. 27, 2001.

This research was supported by grants from the Adolor Corporation, the Joseph Drown Foundation, the Commonwealth of Kentucky Research Challenge Trust Fund and the National Institutes of Health.

The full-time and volunteer faculty of Washington University School of Medicine are the physicians and surgeons of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Washington University School of Medicine

Related Pain Articles from Brightsurf:

Pain researchers get a common language to describe pain
Pain researchers around the world have agreed to classify pain in the mouth, jaw and face according to the same system.

It's not just a pain in the head -- facial pain can be a symptom of headaches too
A new study finds that up to 10% of people with headaches also have facial pain.

New opioid speeds up recovery without increasing pain sensitivity or risk of chronic pain
A new type of non-addictive opioid developed by researchers at Tulane University and the Southeast Louisiana Veterans Health Care System accelerates recovery time from pain compared to morphine without increasing pain sensitivity, according to a new study published in the Journal of Neuroinflammation.

The insular cortex processes pain and drives learning from pain
Neuroscientists at EPFL have discovered an area of the brain, the insular cortex, that processes painful experiences and thereby drives learning from aversive events.

Pain, pain go away: new tools improve students' experience of school-based vaccines
Researchers at the University of Toronto and The Hospital for Sick Children (SickKids) have teamed up with educators, public health practitioners and grade seven students in Ontario to develop and implement a new approach to delivering school-based vaccines that improves student experience.

Pain sensitization increases risk of persistent knee pain
Becoming more sensitive to pain, or pain sensitization, is an important risk factor for developing persistent knee pain in osteoarthritis (OA), according to a new study by researchers from the Université de Montréal (UdeM) School of Rehabilitation and Hôpital Maisonneuve Rosemont Research Centre (CRHMR) in collaboration with researchers at Boston University School of Medicine (BUSM).

Becoming more sensitive to pain increases the risk of knee pain not going away
A new study by researchers in Montreal and Boston looks at the role that pain plays in osteoarthritis, a disease that affects over 300 million adults worldwide.

Pain disruption therapy treats source of chronic back pain
People with treatment-resistant back pain may get significant and lasting relief with dorsal root ganglion (DRG) stimulation therapy, an innovative treatment that short-circuits pain, suggests a study presented at the ANESTHESIOLOGY® 2018 annual meeting.

Sugar pills relieve pain for chronic pain patients
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology.

Peripheral nerve block provides some with long-lasting pain relief for severe facial pain
A new study has shown that use of peripheral nerve blocks in the treatment of Trigeminal Neuralgia (TGN) may produce long-term pain relief.

Read More: Pain News and Pain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to